8-K: Eyenovia Faces Nasdaq Delisting Threat After Share Price Falls Below $1.00

Eyenovia, Inc. has received a notice from Nasdaq that its stock price has fallen below the minimum $1.00 per share requirement for continued listing.

Summary

• Eyenovia, Inc. received a notification from Nasdaq on July 2, 2024, stating that its common stock had closed below the $1.00 minimum bid price for 30 consecutive business days.
• This notice does not immediately affect the listing of Eyenovia's stock, which continues to trade under the symbol EYEN.
• Eyenovia has been granted an initial 180-day period, until December 30, 2024, to regain compliance by having its stock price close at or above $1.00 for at least 10 consecutive business days.
• If Eyenovia fails to regain compliance by December 30, 2024, it may be eligible for an additional 180-day compliance period if it meets other listing requirements and notifies Nasdaq of its intention to cure the deficiency.
• If Eyenovia cannot cure the deficiency, Nasdaq may delist the company's securities, and while Eyenovia can appeal, there is no guarantee of continued listing.
• The company intends to monitor its stock price and consider options to regain compliance.

Sentiment

Score: 3

Explanation: The document indicates a significant negative event with the delisting notice, creating uncertainty about the company's future listing status. The company is facing a challenge to regain compliance.

Positives

• The Nasdaq notice has no immediate effect on the listing of the company's common stock.
• Eyenovia has been granted an initial 180-day period to regain compliance.
• The company may be eligible for an additional 180-day compliance period if it meets certain conditions.

Negatives

• Eyenovia's stock price has fallen below the minimum $1.00 per share requirement for continued listing on Nasdaq.
• The company faces the risk of delisting if it does not regain compliance by December 30, 2024.
• There is no assurance that the company will be able to regain compliance or avoid delisting.

Risks

• The primary risk is the potential delisting of Eyenovia's stock from the Nasdaq Capital Market.
• Failure to regain compliance could negatively impact investor confidence and the company's ability to raise capital.
• The company's stock price may experience further volatility due to the delisting threat.
• There is no guarantee that the company will be able to meet the bid price requirement during any compliance period.

Future Outlook

The company intends to actively monitor its stock price and consider available options to regain compliance, but there is no guarantee of success.

Management Comments

• The company intends to actively monitor the minimum bid price of its common stock and may, as appropriate, consider available options to regain compliance.

Industry Context

This announcement highlights the challenges faced by companies with low stock prices, particularly in maintaining listing requirements on major exchanges like Nasdaq. It is not uncommon for companies to receive delisting notices when their stock price falls below a certain threshold.

Comparison to Industry Standards

• Many companies listed on the Nasdaq Capital Market face similar challenges with maintaining minimum bid price requirements.
• Companies like Eyenovia often implement strategies such as reverse stock splits or capital raises to regain compliance.
• The 180-day compliance period is a standard procedure for companies facing delisting notices on Nasdaq.
• Other companies in the biotech sector with similar market caps have faced similar delisting risks.

Stakeholder Impact

• Shareholders face the risk of potential delisting and a decline in stock value.
• Employees may experience uncertainty about the company's future.
• Creditors may be concerned about the company's financial stability.

Next Steps

• Eyenovia will actively monitor its stock price.
• The company will consider options to regain compliance with Nasdaq listing rules.
• Eyenovia may need to achieve a stock price of $1.00 or more for at least 10 consecutive business days before December 30, 2024.

Key Dates

Keywords

delisting, Nasdaq, compliance, stock price, EYEN, minimum bid price, listing rule